Approval · Notice of Compliance 21692 · 2019
LACOSAMIDE: Notice of Compliance 21692
Issued January 3, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 21692
- Date
- January 3, 2019
- Company
- Jubilant Generics LimitedNoida, Uttar Pradesh, India
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- VIMPAT (Ucb Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| LACOSAMIDE | 02484382 | Approved |
| LACOSAMIDE | 02484390 | Approved |
| LACOSAMIDE | 02484404 | Approved |
| LACOSAMIDE | 02484412 | Approved |
Medicinal ingredients
- LACOSAMIDE 50 MG per TAB
- LACOSAMIDE 100 MG per TAB
- LACOSAMIDE 150 MG per TAB
- LACOSAMIDE 200 MG per TAB